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Abstract
Advances in therapies for younger patients with multiple myeloma have resulted in significant 
improvements in outcome over recent years, on the contrary the progress i
elderly patients has remained more modest. Traditionally, patients   who are not eligible for 
transplantation, like the older patients,  have been treated with the combination of melphalan 
plus prednisone (MP), which leads to responses in 
patients rarely achieve a complete response (CR) and long
with  a  relapse-free  survival  of  approximately  18  months  and  an  overall  survival  (OS)  of 
approximately 3 years.
With  the  arrival  of  novel  agents,  including  the  first
bortezomib, and the immunomodulatory agents, thalidomide and lenalidomide, a shift in the 
management of older patients and/or those not eligible for transplantation has taken place. 
Increasingly, novel agents are now being incorporated into therapy, based on the positive 
findings from clinical trials in this setting, and outcomes have improved accordingly.
Whereas  advances  in  therapies  for  younger 
patients  with  multiple  myeloma  have  resulted  in 
significant  improvements  in  outcome  over  recent 
years, progress in treatments for elderly patients has 
remained more modest.
1 Traditionally, patients who 
are not eligible for transplantation have been treated 
with the combination of melphalan plus prednisone 
(MP),  which  leads  to  responses  in  approximately 
50% of patients; however, patients rarely achieve a 
complete  response  (CR) and  long-term  outcomes 
are  disappointing,  with  a  relapse-free  survival  of 
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Advances in therapies for younger patients with multiple myeloma have resulted in significant 
improvements in outcome over recent years, on the contrary the progress in treatments for 
elderly patients has remained more modest. Traditionally, patients   who are not eligible for 
transplantation, like the older patients,  have been treated with the combination of melphalan 
plus prednisone (MP), which leads to responses in approximately 50% of patients; however, 
patients rarely achieve a complete response (CR) and long-term outcomes are disappointing, 
free  survival  of  approximately  18  months  and  an  overall  survival  (OS)  of 
al  of  novel  agents,  including  the  first–in-class  proteasome  inhibitor, 
bortezomib, and the immunomodulatory agents, thalidomide and lenalidomide, a shift in the 
management of older patients and/or those not eligible for transplantation has taken place. 
reasingly, novel agents are now being incorporated into therapy, based on the positive 
findings from clinical trials in this setting, and outcomes have improved accordingly.
Whereas  advances  in  therapies  for  younger 
patients  with  multiple  myeloma  have  resulted  in 
significant  improvements  in  outcome  over  recent 
years, progress in treatments for elderly patients has 
Traditionally, patients who 
are not eligible for transplantation have been treated 
with the combination of melphalan plus prednisone 
(MP),  which  leads  to  responses  in  approximately 
50% of patients; however, patients rarely achieve a 
term  outcomes 
free  survival  of 
approximately  18  months  and  an  overall  survival 
(OS) of approximately 3 years.
2
With the arrival of novel agents, including the 
first–in-class proteasome inhibitor, bortezomib, and
the  immunomodulatory  agents,  thalidomide  and 
lenalidomide,  a  shift  in  the  management  of  older 
patients and/or those not eligible for transplantation 
has taken place. Increasingly, novel agents are now 
being  incorporated  into  therapy,  based  on  the 
positive findings from clinical trials in this setting, 
and outcomes have improved accordingly. 
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Table 1: Summary of five MPT Phase III trials conducted in the upfront setting.
Regimen n CR+PR (%) CR (%) PFS/EFS/TTP OS Reference
Thal/MP vs 
MP
129
126
76
48
16
4
21.8 m
14.5 m
45 m
47.6 m
Palumbo et al.
Blood 2008; 112:3107–
3114
5
Thal/MP vs 
MP
191
124
76
35
13
2
27.5 m
17.8 m
51.6 m
33.2 m
Facon, et al.
Lancet 2007; 370:1209–
1218
3
Thal/MP vs
MP (>75 y)
113
116
62
31
7
1
24.1 m
19 m
45.3 m
27.7 m
Hulin, et al.
Blood 2007;110 (Abstract 
75)
4
Thal/MP* vs 
MP 363 42
28
6
†
3
†
20 m
18 m
29 m
33 m
Gulbrandsen et al.
Haematologica 2008;93 
(Abstract 209)
6
Thal/MP vs 
MP
152
149
66
47
2
2
EFS 13 m vs 9 m
PFS 14 m vs 10 m
37 m
30 m
Wijermans et al. Blood
2008;112 (Abstract 649)
7
*Thal doses: 200–400 mg. 
†CR + near CR 
Specifically,  a  number  of  studies  have 
investigated  the  addition  of  novel  agents  to  the 
traditional  MP  regimen.  The  combination  of  MP 
plus  thalidomide  has  been  investigated  in  five 
randomized trials.
4–9 In all studies, the addition of 
thalidomide  to  MP  resulted  in  a  significant 
improvement  in  overall  response  rate  (ORR)  and 
CR  rates,  as  well  time  to  progression  (TTP), 
progression-free  survival  (PFS)  or  event-free 
survival (EFS) (Table 1). A significant benefit in 
terms of  OS, however,  was only  seen in  the two 
studies  conducted  by  the  Intergroupe  Français  du 
Myélome  [IFM]  (P=0.0006,  P=0.03).
4,5 The  most 
frequent grade 3/4 adverse events reported included 
hematological  toxicities,  thromboembolism, 
infections, and gastrointestinal side-effects.
4,6
Thalidomide  has  also  been  combined  with 
dexamethasone in a trial conducted by Ludwig et 
al.
10 evaluating  elderly  patients  with  newly 
diagnosed multiple myeloma. Compared with MP, 
thalidomide  plus  dexamethasone  (TD)  resulted  in 
higher ORR (68% versus 50%, P=0.0023) and CR 
plus very good partial response (VGPR) rates (26% 
versus  13%,  P=0.0066).  TTP  (21.2  versus  29.1 
months, P=0.2) and PFS (16.7 versus 20.7 months, 
P=0.1)  were  similar  in  both  arms.  However,  MP 
proved superior to TD in terms of OS (49.4 versus 
41.5  months,  P=0.024).  Notably,  the  number  of 
early deaths within the first year was significantly 
higher in the TD arm (28% versus 16%, P=0.014). 
In  addition,  TD resulted  in  a higher  incidence of 
toxicity, which was observed particularly in patients 
older  than  75  years  and  those  with  poor 
performance status. 
Lenalidomide  has  also  been  studied  in the 
elderly population. A Phase I/II trial by Palumbo et 
al.
6 which  investigated  the  combination  of 
lenalidomide  with  MP  in  elderly  patients  with 
newly diagnosed multiple myeloma yielded positive 
results, with impressive ORR and a favourable side 
effect  profile.  These  data  require  confirmation  in 
randomized  clinical  trials,  and  a  number  are 
ongoing, with results anticipated soon. In addition, 
data  from  the  randomized  ECOG  EA403  study 
comparing  lenalidomide  with  high  dose 
dexamethasone (RD), versus lenalidomide with low 
dose dexamethasone (Rd), have shown efficacy in 
older patients, with promising ORR, PFS and OS 
but  significant  toxicity  with  the  higher  dose 
dexamethasone such that OS proved inferior with 
RD compared to Rd, confirming the importance of 
using relatively  steroid-sparing  approaches  in  this 
population.
7
The  combination  of  bortezomib  with  MP 
(VMP)  has  been  explored  in  the  large  Phase  III 
VISTA  trial  and  was  found  to  be  significantly 
superior to MP in terms of ORR and CR rates, TTP, 
and 3-year OS.
11,12 The ORR, determined using the 
stringent  European  Group  for  Blood  and  Marrow 
Transplantation  criteria,  was  71%  with  VMP 
compared  with  35%  with  MP,  with  an 
immunofixationnegative CR rate of 30% with VMP 
versus  4%  with  MP  (P<0.001).  TTP  was 
significantly longer in the VMP arm than in the MP 
arm  (24  months  versus  16.6  months,  P<0.001). 
Although median OS was not reached in either arm 
after  a  median  follow-up  of  25.9  months,  VMP 
demonstrated  a  significantly  superior  3-year  OS 
compared  with  MP:  72%  with  VMP  versus  59% 
with  MP (P=0.0032).  Fewer patients in the VMP 
versus MP arm required subsequent therapy (38% 
versus  57%).  The  time  to  next  therapy  was  28.1 
months  for  VMP  versus  19.2  months  for  MP 
(P<0.000001). In addition, patients receiving VMP 
had  a  significantly  longer  treatment-free  interval 
(TFI)  compared  with  those  receiving  MP  (16.6 
versus  8.4  months,  P<0.000001).  Subanalyses  of 
the  VISTA  study  showed  that  VMP  remains Medit J Hemat Infect Dis 2010; 2(2); Open Journal System 
effective in patients with renal impairment, in those 
with  cytogenetic  abnormalities,  and  that  the 
concomitant  use  of  erythropoiesis-stimulating 
agents does not negatively impact on PFS and OS 
or increase the risk of thromboembolic events.
11–14
The main differences in the incidence of grade 
3/4 adverse events between the VMP and MP arms 
were seen  for  gastrointestinal  side  effects, 
peripheral  neuropathy  (PN),  and  herpes  zoster 
infection, which were found to be more frequent in 
the  VMP  arm,  with  the  latter  proving  readily 
manageable with anti-viral prophylaxis. PN grade 3 
was observed in 13% of patients, with grade 4 PN 
observed  in  <1%  of  patients  receiving  VMP. 
However, PN was reversible in most patients; 79% 
of PN events improved ( 1 grade) in a median of 
1.9  months  and  79%  of  PN  events  completely 
resolved in a median of 5.7 months. 
The  VISTA  trial  demonstrated  that  VMP  is 
significantly  superior  to  MP  in  terms  of  TTP 
(P<0.001),  CR  (P<0.001),  ORR  (P<0.001),  TFI 
(P<0.000001), and OS (P=0.0032). These data have 
significant implications for the treatment of patients 
with newly diagnosed disease who are not eligible 
for transplantation, including those with  high risk 
disease; results from this controlled trial show that 
VMP should be considered a new standard of care 
for these patients and provided the basis for FDA 
and EMEA approval for the use of bortezomib in 
the upfront setting in 2008.
Two ongoing studies in the elderly population 
are currently investigating reduced bortezomib dose 
intensity  in  combination  with  MP.  Instead  of  the 
twice-weekly  dose,  bortezomib  is  administered 
once weekly. Early results indicate that significant 
efficacy  is  maintained  with  the  less  frequent 
bortezomib schedule (Table 2), while tolerability is 
increased substantially. Notably, grade 3/4 PN was 
only 2% or 5% with the reduced dose VMP regimen 
in  the  two  studies.
15,16 Moreover,  the  rate  of 
treatment discontinuations was low in both studies 
(8% and  10%).
15,  16 Although  longer follow-up is 
needed to assess PFS and OS, the results suggest 
that  bortezomib  administered  once  weekly  in 
combination with MP is effective in elderly patients 
with increased tolerability, suggesting that this may 
be  a  particularly  useful  regimen  in  patients  who 
cannot tolerate the full-dose VMP regimen, such as 
very elderly or frail patients. 
Combinations  of  novel  agents,  informed  by 
preclinical studies
17, have also been studied in older 
patients as part of Phase I/II trials, with promising 
results  to  date
18.  Specifically,  the  combination  of 
lenalidomide,  bortezomib  and  dexamethasone  (so 
called RVD) has shown an ORR of 100% with a 
VGPR of 74% and nCR/CR of 44%, with patients 
up to the age of 86 years included, and a substantial 
portion over the age of 70.  No treatment mortality 
has  been  reported  and  toxicities  have  proven 
manageable, with low rates of both significant PN 
(3%)  and  DVT  (5%)  seen. Moreover,  responses 
have been durable, with activity in high risk disease 
also noted.
18
In  spite  of  well  documented  improvement  in 
patient outcomes associated with the introduction of 
novel  agents  in  multiple myeloma 
19,  nearly  all 
patients relapse and require additional therapy.  As 
is  true  for  newly  diagnosed  multiple  myeloma, 
novel  agents  have  assumed  an  increasingly 
important role in the management of patients with 
relapsed and refractory disease.  
Following a series of encouraging phase I/II clinical 
trials
20,  21, the efficacy of lenalidomide in relapsed 
and refractory MM was unequivocally demonstrated 
in  two  large,  phase  III  trials  comparing 
lenalidomide  plus  dexamethasone  to  lenalidomide 
plus placebo, the MM-009 
22 and MM-010 
23studies.  
The  median  age  of  patients  treated  with 
lenalidomide and  dexamethasone  was 64  in  MM-
009 and 63 in MM-010, while the median age of 
those  in  dexamethasone  arm  was  62  and  64, 
respectively.  However,  both  studies  included  a 
substantial  portion  of  elderly  patients.  In  both 
studies,  lenalidomide  plus  dexamethasone  was 
superior to dexamethasone plus placebo in terms of 
OR (61% versus 19.9%, P < 0.001 in MM-009 and 
Table 2: Bortezomib Phase III trials in upfront setting
Regimen n CR+PR (%) CR (%) PFS/EFS/
TTP OS Reference
VISTA:
VMP vs 
MP
337
331
71
35
30
4
24 m
16.6 m
3-year OS:
72%
59%
San Miguel et al. NEJM
2008; 359:906–917
9
GIMEMA:
VMPT vs 
VMP
177
177
87
82
39
21
2-year PFS:
84%
76%
3-year OS:
90%
89%
Palumbo IMW 2009 
(Abstract 117)
14
PETHEMA/GEM:
VMP vs 
VTP
130
130
81
81
22
27
2-year PFS:
72%
65%
2-year OS:
88%
93%
Mateos IMW 2009 
(Abstract 154)
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Figure 1.
60%  versus  24%,  P  <  0.001  in  MM-010),  CR
(14.1%  versus  0.6%,  P  <  0.001  in  MM-009  and 
15.9% versus 3.4% in MM-010), TTP (11.1 months 
versus 4.7 months, P < 0.001 in MM-009 and 11.3 
months versus 4.7 months, P < 0.001 in MM-010), 
as well as OS (29.6 months versus 20.2 months, P < 
0.001  in  MM-009  and  median  OS  not  reached 
versus 20.6 months in MM-010, with hazard ratio 
for  death  0.66).  Grade  3/4  toxicities  were  more 
common  with  lenalidomide  and  dexamethasone, 
particularly  neutropenia  and  venous 
thromboembolism.    Based  on  these  studies, 
lenalidomide  in  combination  with  dexamethasone 
has  received  approval  from  both  the  FDA  and 
EMEA  for  treatment  of  relapsed  and  refractory 
multiple myeloma.  
Bortezomib  is  also  an  effective  treatment 
strategy in patients with relapsed multiple myeloma.  
This was suggested by phase  I/II trials 
24,25,26  and 
confirmed in a randomized phase III study wherein 
patients  received  either  bortezomib  or  high-dose 
dexamethasone ) 
27.   The median age was 62 in the 
bortezomib  arm  and  61  in  the  high-dose 
dexamethasone arm, an age distribution reflecting 
the  age  demographics  of  multiple  myeloma  with 
again  a  proportion  of  older  patients  included.  
Bortezomib outperformed high dose dexamethasone 
in terms of OR (38% versus 18%, P < 0.001), CR 
(6%  versus  1%,  P  <  0.001),  TTP  (6.22  months 
versus  3.49  months,  P  <  0.001),  and  one-year 
survival rate (80% versus 66%, P = 0.003).  In an 
updated analysis including final time to event data, 
the OR and CR rates in the bortezomib arm of this 
trial were 43% and 9% 
28.   The median survival for 
bortezomib-treated patients in this analysis was 29.8 
months versus 23.7 months in the dexamethasone 
group.    Bortezomib  was  associated  with  a  higher 
rate of grade 3/4 toxicities (75% versus 60%).  PN 
was  more  common  with  bortezomib  (36%  versus 
9%), although in most instances PN was grade < 2 
and reversible with suggested dose modification or 
treatment  discontinuation.    Thrombocytopenia 
occurred  in  35%  of  bortezomib-treated  patients 
versus  11%  among  those  who  received 
dexamethasone, but was cyclical with platelet count 
recovery  during  the  10-day  rest  period  and  not 
associated  with  an  increased  incidence  of 
significant  bleeding  events.    The  incidence  of 
herpes-zoster  reactivation  was  also  higher  in  the 
bortezomib  arm  (13%  versus  5%;  P  <  0.001), 
confirming  the  need  for  -antiviral  prophylaxis  in
these patients.  
As in the setting of newly  diagnosed disease, 
regimens  involving  combinations  of  novel  agents 
are  undergoing  evaluation  in  relapsed  multiple 
myeloma and  have  produced  promising results  to 
date.   In  a phase  I/II  study involving 85  patients 
with  advanced  disease,  bortezomib,  thalidomide, 
and  dexamethasone  (VTD)  yielded  an  OR  rate 
(minimal response [MR] or greater) of 79% and a 
nCR rate of 22% 
29.   RVD has also been evaluated 
in refractory multiple myeloma; in a phase II study 
involving  63  patients,  the  combination  was  an 
associated with  at  least  an  MR  in  86%,  a  PR  or 
better in 67%, and a nCR or better in 24% ) 
30.  The 
regimen  has  been  well  tolerated  with  only  one 
episode of grade 3 PN, very rare DVT and primarily 
grade 1-2 myelosuppression.  
Although the management of multiple myeloma 
in  older  patients  not  eligible  for  transplantation 
provides  considerable  challenges,  there  is  now 
reason for greater optimism. A range of novel agent 
combinations  are  available  which  have 
demonstrated superior efficacy over the traditional 
combination chemotherapy, such as MP, indicating 
that  MP  should  no  longer  be  considered  the 
standard of care in this population. Ongoing studies 
will  establish  optimal  dosing  and  treatment 
schedules for different populations, with the aim of 
maximizing  rate  and  frequency  of  response, 
durability of remission and improving tolerability, 
especially  in  elderly  and/or  more  frail  patients. 
Future  trials  will  also  evaluate  the  integration  of 
newer  agents  currently  under  development  in  the 
advanced setting (please see figure 1), with the goal 
of  further  improving  patient  outcome,  as  well  as 
establishing doses  and schedules in  older patients 
associated  with  better  efficacy  in  this  particular 
population.
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